

This material is an English translation of the press release announced on October 7, 2024 in Japanese, and the Japanese release is given priority about the content and the interpretation.

October 7, 2024

## Notification of Open Innovation in SAGA Global Research Center

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture; President: NAKATOMI, Kazuhide; hereinafter “Hisamitsu Pharmaceutical”) hereby announces that as part of our open innovation activities, we are looking for collaborative partnerships with universities, research institutes, and companies in both Japan and overseas to promote pharmaceutical R&D.

In our 7<sup>th</sup> Mid-term Management Policy for FY2021 - 2025, we have set the goal of strengthening our research and development capabilities (formulation development and reconstruction of our research structure). The new SAGA Global Research Center (370-1, Yomesaka, Himekata-Machi, Tosu, Saga), which was completed on February 29, 2024, in an effort to develop innovative technologies and discover new drugs by incorporating diverse perspectives and ideas.

To achieve this, joint research with collaborative partners through open innovation is essential. For this reason, we have published the following Wish List of research projects we would like to pursue and are widely soliciting proposals for joint research related to these topics:

### **TDDS (Transdermal Drug Delivery System) Related Technology**

Formulation Technology 1: Technologies or devices enhancing transdermal absorption of drugs

Formulation Technology 2: Technologies reducing skin irritation

### **Dermatology Related Research**

Research Topic: Dermatology related joint research

### **Drugs for TDDS**

Drug Candidates: Existing drugs or novel drug candidates suitable for transdermal products

If you have any questions about the Wish List or would like to propose a joint research project, please use the “Inquiry Form” on the website.

“Open Innovation in SAGA Global Research Center” website:


<https://global.hisamitsu/operations/sgrc-oi.html>

The SAGA Global Research Center is a research institute that integrates the existing research centers in Tosu City, Saga Prefecture and Tsukuba City, Ibaraki Prefecture. The SAGA Global Research Center integrates the functions required for TDDS formulation development, including efficacy and safety evaluation, formulation prototyping, and analytical evaluation, enabling consistent and speedy formulation development.



SAGA Global Research Center

We have open innovation spaces, a joint experiment space (open laboratory), and a collaboration office as a place to interact with partners, creating an environment where researchers can work together on innovation. Equipment specific to TDDS drug development, such as skin permeation test equipment, is also available to partners through joint collaboration. Our researchers specializing in TDDS formulations development, will support you in the trial production and evaluation of TDDS formulations.



Open innovation space



Open laboratory



Collaboration office

In addition, the SAGA Global Research Center is easily accessible by car as it is located right next to the Tosu Interchange at the intersection of the Kyushu Expressway, Nagasaki Expressway, and Oita Expressway. There are universities and research institutes in the surrounding area, and the SAGA Global Research Center has excellent access to these institutions.

We will continue to contribute to improving the quality of life of people around the world by further accelerating research and development through open innovation activities and delivering a variety of products to customers around the world as quickly as possible.